What is HC Wainwright’s Forecast for DVAX Q2 Earnings?

Dynavax Technologies Co. (NASDAQ:DVAX) – Research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Dynavax Technologies in a research report issued on Tuesday, January 14th. HC Wainwright analyst E. White anticipates that the biopharmaceutical company will earn $0.08 per share for the quarter. HC Wainwright has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share. HC Wainwright also issued estimates for Dynavax Technologies’ Q3 2025 earnings at $0.12 EPS, FY2025 earnings at $0.35 EPS and FY2026 earnings at $0.45 EPS.

Separately, StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $12.39 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $14.30. The company has a market cap of $1.63 billion, a price-to-earnings ratio of 95.32 and a beta of 1.34. The stock has a fifty day moving average price of $12.78 and a 200-day moving average price of $11.66.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. bought a new position in shares of Dynavax Technologies in the 3rd quarter valued at $8,291,000. Entropy Technologies LP acquired a new stake in Dynavax Technologies in the third quarter valued at about $462,000. Nordea Investment Management AB grew its position in Dynavax Technologies by 42.7% in the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after acquiring an additional 232,690 shares during the last quarter. Bank of Montreal Can grew its position in Dynavax Technologies by 8.3% in the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock valued at $11,848,000 after acquiring an additional 82,449 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Dynavax Technologies during the second quarter worth about $17,615,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.